Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The proposed study will assess the efficacy, safety and tolerability of once daily dosing of
Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC)
mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines, for
treatment of mycobacterium abscessus lung disease.
Phase:
Phase 2
Details
Lead Sponsor:
Kevin Winthrop
Collaborators:
Insmed Incorporated The University of Texas Health Science Center at Tyler